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istics were similar between treatment groups with regard to
age, weight, cancer type and Hb. The proportion of patients
transfused was similar between groups (~30%). Mean Hb
values were consistently higher in the EPO group compared to
the DARB group at Weeks 4, 8, 12, and 16. A repeated mea-
sures model showed a signiﬁcant Hb increase from BL at each
timepoint assessed in both groups as well as a signiﬁcant dif-
ference between the two groups. Mean cumulative administered
dose was 342,959 Units for EPO and 1239 mcg for DARB with
overall ESA drug cost signiﬁcantly lower in the EPO group
compared to the DARB group (EPO $4503, DARB $5669
p < 0.001). CONCLUSION: In patients with Hb < 10 g/dL
prior to ESA initiation, mean Hb levels were higher in the EPO
group than the DARB group throughout the study, with ESA
drug costs 21% lower in the EPO group than the DARB group.
Such ﬁndings inform decision-makers on ESA-associated
outcomes based on initiation as imposed in certain coverage
policies.
PCN85
EFFECT OF AGE AND PLACE OF RESIDENCE ON
COLORECTAL CANCERTREATMENTS IN NEBRASKA CANCER
REGISTRY FROM 1998TO 2003
Sankaranarayanan J1,Watanabe-Galloway S2, Sun J1, Qiu F1,
Boilesen E1,Thorson AG1
1University of Nebraska Medical Center, Omaha, NE, USA, 2Univeristy
of Nebraska Medical Center, Omaha, NE, USA
OBJECTIVE: The National Cancer Institute indicates surgery,
chemotherapy, and/or radiation treatments in colorectal cancer
(CRC). Data on the effect of age and place of residence on
accessing CRC treatments in the Midwest region of United States
is limited. Therefore, using Nebraska Cancer Registry we tested
the hypothesis that CRC patients’ residence-county and age
would be associated with receipt of surgery, radiation, and che-
motherapy treatments. METHODS: In a retrospective study, we
examined treatments of 6813 CRC patients identiﬁed by incident
ICD-O CM codes between January 1998, and December 2003
from the Nebraska Cancer Registry data. In multivariate logistic
regression analyses, we studied the association of age and the
year 2003 Urban Inﬂuence Code based residence-county with
each of the three CRC treatments. RESULTS: After adjusting
for patient’s demographics, insurance payer, county-speciﬁc
provider-to-population ratio, and stage and anatomical site,
CRC patients living in small urban counties were more likely to
receive chemotherapy than were those living in rural counties
(adjusted Odds-Ratio, OR, 1.53; 95% conﬁdence-interval, CI:
1.25–1.88, p < 0.001). However, there were no signiﬁcant rural-
urban differences in receiving any CRC treatment. Compared
with 19-to-64-year-olds, patients aged 75 years and older with
local CRC stage were less likely to receive surgery (OR, 0.22;
95% CI: 0.07–0.76, p < 0.001), patients aged 75 years and older
were less likely to receive radiation (OR, 0.36; 95% CI: 0.24–
0.55, p < 0.0001), and patients aged 75 years and older were less
likely to receive chemotherapy (OR, 0.21; 95% CI: 0.16–0.27,
p < 0.0001). CONCLUSION: Nebraska CRC patients living in
rural counties were less likely to receive chemotherapy than were
those living in small urban counties. Elderly CRC patients were
less likely to receive surgery, radiation, and chemotherapy treat-
ments. Despite limitations of registry data, these ﬁndings warrant
the attention of decision-makers to age and geographic access
issues in planning future delivery of CRC treatments.
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OBJECTIVE: To assess current real-world utilization of ESAs
in patients with MDS, recent epoetin alfa (EPO) and darbepo-
etin alfa (DARB) dosing patterns and ESA treatment costs were
examined. METHODS: A retrospective analysis was conducted
using medical claims from approximately 45 health plans
nationwide during the period of Janaury 2004–June 2007.
Patients included in the study were 18 years old, had 1
claim for MDS (ICD-9 code: 238.7) prior to initiating ESA
therapy, and were newly initiated on EPO or DARB with 2
doses of either drug during the treatment period. Patients with
cancer before initiating ESA treatment for MDS were excluded.
The study period terminated with the last ESA treatment dose,
end of data availability, initial AML diagnosis, or initial stem
cell transplant, whichever occurred ﬁrst. Mean cumulative ESA
dose was used to calculate ESA cost (based on October 2007
WAC) and dose ratio (Units EPO : mcg DARB). RESULTS: The
study population consisted of 275 patients who received EPO
and 155 patients who received DARB. Mean age and gender
distribution was similar between the two groups. Mean treat-
ment duration was also similar for both groups (EPO: 75 days;
DARB: 71 days; p = 0.638). The mean cumulative ESA dose
administered was 374,415 Units for EPO and 1475 mcg for the
DARB group, corresponding to a dose ratio of 254:1 (Units
EPO: mcg DARB). Based on these doses, ESA cost was $2139
(31%) less for EPO than for DARB (EPO: $4688; DARB:
$6827; p = 0.010). CONCLUSION: These real-life clinical
practice ﬁndings in the MDS population show signiﬁcantly
lower drug cost in the EPO group compared to the DARB
group and a dose ratio of 254:1 (Units EPO : mcg DARB)
between the two agents.
PCN87
USE OF PHARMACOECONOMIC MESSAGES IN ONCOLOGY
PROMOTIONAL MATERIALS
Kalpas E, Subrahmanian T, Stern L
Analytica International, New York, NY, USA
OBJECTIVE: To evaluate the presence of pharmacoeconomic
messages in the US, France, Germany, Italy, Spain, and UK for
ten representative oncology products (Alimta, Avastin, Gemzar,
Herceptin, Neulasta, Novantrone, Sutent, Tarceva, Taxotere,
and Velcade). METHODS: This qualitative assessment covered
the following data sources: 1) Government websites (Canadian
Agency for Drugs and Technologies in Health, National Insti-
tute for Health and Clinical Excellence, Institut für Qualität
und Wirtschaftlichkeit im Gesundheitswesen, La Haute
Autorité de santé, and Cochrane Reviews); 2) company spon-
sored product websites; 3) FDA and EMEA products labels;
and 4) promotional materials (detail aid brochures, direct mail,
and professional journal/newsletter ads). These data sources
were searched for relevant pharmacoeconomic messaging
including statements regarding cost, QoL, utility, patient pre-
ference, etc. RESULTS: While health technology assessments
have a clear impact on market access, speciﬁc examples of
pharmacoeconomic data in promotional messaging was limited.
Pharmacoeconomic messages, with particular focus on QoL,
were more prominent in promotional materials of oncology
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